Liquid Biopsy in Tumor Genetic Diagnosis

Overview

Journal Dtsch Arztebl Int

Specialties General Medicine
Public Health

Date 2018 Mar 29

PMID 29587961

Citations 28

Authors

Andreas Jung

Thomas Kirchner

Affiliations

Soon will be listed here.

Abstract

Background: Liquid biopsy involves the analysis of cell-free nucleic acids, mainly circulating free DNA (cfDNA), in bodily fluids such as blood. The obtaining of specimens is easier for patients and less invasive than tissue biopsy, but the method has certain limitations.

Methods: This review is based on pertinent publications retrieved by a selective literature search.

Results: Because the concentration of cfDNA in plasma is less than 0.001%, special amplifying techniques must be used to enable a search for specific mutations. Liquid biopsy can be used in patients with non-small cell lung cancer (NSCLC) if no tissue is available for biopsy; when performed for this indication, it has 67% sensitivity and 94% specificity. If liquid biopsy does not reveal a mutation, this may be due either to the absence of the mutation in the tumor or to the inadequate sensitivity of the measuring technique. This uncertainty associated with negative findings can be reduced by the simultaneous demonstration of reference mutations derived from a primary tumor tissue analysis. In comparison to tissue studies, the search for tumor-specific mutations by liquid biopsy is 70% sensitive and 69% specific; this corresponds to a positive predictive value of 86% and a negative predictive value of 46%.

Conclusion: Liquid biopsy and tumor tissue analysis are complementary, rather than alternative, techniques for therapeutically relevant genetic investigation of tumors. Comparative studies are needed so that further indications can be determined for liquid biopsy in the diagnostic evaluation of cancer.

Citing Articles

Next generation sequencing and genomic mapping: towards precision molecular diagnosis of lung cancer in Morocco.

Morjani O, Mounaji N, Ghaouti M, Errihani H, El Fahime E, Lakhiari H Pan Afr Med J. 2025; 49:75.

PMID: 39989937 PMC: 11846000. DOI: 10.11604/pamj.2024.49.75.45306.

Establishment of liquid biopsy procedure for the analysis of circulating cell free DNA, exosomes, RNA and proteins in colorectal cancer and adenoma patients.

ceri A, Somborac-Bacura A, Fabijanec M, Hulina-Tomaskovic A, Matusina M, Detel D Sci Rep. 2024; 14(1):26925.

PMID: 39506031 PMC: 11541997. DOI: 10.1038/s41598-024-78497-x.

Droplet Digital PCR as a Molecular Tool for the Detection of the T790M Mutation in NSCLC Patients with the Activating Mutations.

Durgut S, Salihefendic L, Pecar D, ceko I, Mulahuseinovic N, Izmirlija M Balkan J Med Genet. 2024; 26(2):21-26.

PMID: 38482255 PMC: 10932593. DOI: 10.2478/bjmg-2023-0020.

Innovations in Thoracic Oncology and the Promise of Liquid Biopsies with Dr. Luis Raez.

Cortiana V, Van de Kieft A, Chorya H, Gambill J, Park C, Leyfman Y Cancers (Basel). 2024; 16(4).

PMID: 38398189 PMC: 10886586. DOI: 10.3390/cancers16040799.

Cell-Free Tumor DNA Detection-Based Liquid Biopsy of Plasma and Bile in Patients with Various Pancreatic Neoplasms.

Jain M, Atayan D, Rakhmatullin T, Dakhtler T, Popov P, Kim P Biomedicines. 2024; 12(1).

PMID: 38255325 PMC: 10813046. DOI: 10.3390/biomedicines12010220.

References

McAllister S, Weinberg R . The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis. Nat Cell Biol. 2014; 16(8):717-27. PMC: 6220424. DOI: 10.1038/ncb3015. View

Mandel P, Metais P . Nuclear Acids In Human Blood Plasma. C R Seances Soc Biol Fil. 1948; 142(3-4):241-3. View

Bettegowda C, Sausen M, Leary R, Kinde I, Wang Y, Agrawal N . Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014; 6(224):224ra24. PMC: 4017867. DOI: 10.1126/scitranslmed.3007094. View

Parkinson D, Dracopoli N, Petty B, Compton C, Cristofanilli M, Deisseroth A . Considerations in the development of circulating tumor cell technology for clinical use. J Transl Med. 2012; 10:138. PMC: 3478228. DOI: 10.1186/1479-5876-10-138. View

Siravegna G, Bardelli A . Genotyping cell-free tumor DNA in the blood to detect residual disease and drug resistance. Genome Biol. 2014; 15(8):449. PMC: 4281953. DOI: 10.1186/s13059-014-0449-4. View

Li M, Diehl F, Dressman D, Vogelstein B, Kinzler K . BEAMing up for detection and quantification of rare sequence variants. Nat Methods. 2006; 3(2):95-7. DOI: 10.1038/nmeth850. View

Oxnard G, Thress K, Alden R, Lawrance R, Paweletz C, Cantarini M . Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2016; 34(28):3375-82. PMC: 5035123. DOI: 10.1200/JCO.2016.66.7162. View

Diehl F, Li M, Dressman D, He Y, Shen D, Szabo S . Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A. 2005; 102(45):16368-73. PMC: 1283450. DOI: 10.1073/pnas.0507904102. View

Camidge D, Pao W, Sequist L . Acquired resistance to TKIs in solid tumours: learning from lung cancer. Nat Rev Clin Oncol. 2014; 11(8):473-81. DOI: 10.1038/nrclinonc.2014.104. View

10.

Volik S, Alcaide M, Morin R, Collins C . Cell-free DNA (cfDNA): Clinical Significance and Utility in Cancer Shaped By Emerging Technologies. Mol Cancer Res. 2016; 14(10):898-908. DOI: 10.1158/1541-7786.MCR-16-0044. View

11.

Calverley D, Phang T, Choudhury Q, Gao B, Oton A, Weyant M . Significant downregulation of platelet gene expression in metastatic lung cancer. Clin Transl Sci. 2011; 3(5):227-32. PMC: 3427741. DOI: 10.1111/j.1752-8062.2010.00226.x. View

12.

Sarwat M, Yamdagni M . DNA barcoding, microarrays and next generation sequencing: recent tools for genetic diversity estimation and authentication of medicinal plants. Crit Rev Biotechnol. 2014; 36(2):191-203. DOI: 10.3109/07388551.2014.947563. View

13.

Mao C, Yuan J, Yang Z, Fu X, Wu X, Tang J . Blood as a Substitute for Tumor Tissue in Detecting EGFR Mutations for Guiding EGFR TKIs Treatment of Nonsmall Cell Lung Cancer: A Systematic Review and Meta-Analysis. Medicine (Baltimore). 2015; 94(21):e775. PMC: 4616411. DOI: 10.1097/MD.0000000000000775. View

14.

Alix-Panabieres C, Pantel K . Challenges in circulating tumour cell research. Nat Rev Cancer. 2014; 14(9):623-31. DOI: 10.1038/nrc3820. View

15.

Bruckl W, Wirtz R, Bertsch T, Ficker J, Jung A . [Liquid Biopsy: Detection of Molecular Markers for Treatment Decisions in Lung Cancer]. Pneumologie. 2017; 71(3):151-163. DOI: 10.1055/s-0042-123803. View

16.

Spornraft M, Kirchner B, Haase B, Benes V, Pfaffl M, Riedmaier I . Optimization of extraction of circulating RNAs from plasma--enabling small RNA sequencing. PLoS One. 2014; 9(9):e107259. PMC: 4167851. DOI: 10.1371/journal.pone.0107259. View

17.

Fenizia F, De Luca A, Pasquale R, Sacco A, Forgione L, Lambiase M . EGFR mutations in lung cancer: from tissue testing to liquid biopsy. Future Oncol. 2015; 11(11):1611-23. DOI: 10.2217/fon.15.23. View

18.

Janne P, Yang J, Kim D, Planchard D, Ohe Y, Ramalingam S . AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 2015; 372(18):1689-99. DOI: 10.1056/NEJMoa1411817. View

19.

Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A . Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol. 2013; 10(8):472-84. DOI: 10.1038/nrclinonc.2013.110. View

20.

Meyerson M, Gabriel S, Getz G . Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet. 2010; 11(10):685-96. DOI: 10.1038/nrg2841. View